Catalent, Inc. (CTLT) EPS Estimated At $0.59

August 13, 2018 - By Darrel Chase

Catalent, Inc. (NYSE:CTLT) LogoInvestors sentiment decreased to 1.16 in 2018 Q1. Its down 0.28, from 1.44 in 2017Q4. It fall, as 23 investors sold Catalent, Inc. shares while 85 reduced holdings. 37 funds opened positions while 88 raised stakes. 127.42 million shares or 2.50% less from 130.69 million shares in 2017Q4 were reported.
Raymond James Assoc reported 136,353 shares. New York-based Bluemar Capital Mgmt Ltd Liability Company has invested 1.33% in Catalent, Inc. (NYSE:CTLT). Us National Bank & Trust De accumulated 1,317 shares. Deutsche Bancorporation Ag, Germany-based fund reported 250,880 shares. Lombard Odier Asset Mngmt (Usa) Corporation has 0.25% invested in Catalent, Inc. (NYSE:CTLT) for 85,000 shares. Barclays Plc invested in 0% or 38,900 shares. Ls Llc has invested 0.03% in Catalent, Inc. (NYSE:CTLT). State Of Wisconsin Board owns 134,500 shares or 0.02% of their US portfolio. Viking L P invested 0.37% of its portfolio in Catalent, Inc. (NYSE:CTLT). Td Asset Mgmt Inc reported 303,773 shares. Axa reported 0.03% in Catalent, Inc. (NYSE:CTLT). 5,880 are owned by Caprock Grp Inc. Denver Investment Llc reported 17,141 shares. Fuller Thaler Asset Mngmt stated it has 0.07% of its portfolio in Catalent, Inc. (NYSE:CTLT). Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Catalent, Inc. (NYSE:CTLT).

Since March 8, 2018, it had 0 insider buys, and 2 sales for $473,717 activity. $379,628 worth of Catalent, Inc. (NYSE:CTLT) was sold by Downie William.

Analysts expect Catalent, Inc. (NYSE:CTLT) to report $0.59 EPS on August, 28 before the open.They anticipate $0.05 EPS change or 7.81 % from last quarter’s $0.64 EPS. CTLT’s profit would be $85.47 million giving it 17.00 P/E if the $0.59 EPS is correct. After having $0.38 EPS previously, Catalent, Inc.’s analysts see 55.26 % EPS growth. The stock decreased 0.25% or $0.1 during the last trading session, reaching $40.12. About 509,640 shares traded. Catalent, Inc. (NYSE:CTLT) has risen 9.81% since August 13, 2017 and is uptrending. It has underperformed by 2.76% the S&P500.

Catalent, Inc. (NYSE:CTLT) Ratings Coverage

Among 2 analysts covering Catalent (NYSE:CTLT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalent had 2 analyst reports since March 21, 2018 according to SRatingsIntel. The stock of Catalent, Inc. (NYSE:CTLT) has “Outperform” rating given on Wednesday, March 21 by Raymond James. KeyBanc Capital Markets upgraded the shares of CTLT in report on Wednesday, March 28 to “Overweight” rating.

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. The company has market cap of $5.81 billion. It operates through three divisions: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. It has a 82.89 P/E ratio. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

Another recent and important Catalent, Inc. (NYSE:CTLT) news was published by which published an article titled: “Catalent (CTLT) Sees Q4 Revenue of 683 to $686 Million” on July 23, 2018.

Catalent, Inc. (NYSE:CTLT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.